Zim Laboratories Ltd (NSE:ZIMLAB)
₹ 116.59 -3.08 (-2.57%) Market Cap: 5.68 Bil Enterprise Value: 6.84 Bil PE Ratio: 47.88 PB Ratio: 2.32 GF Score: 49/100

Q4 2025 ZIM Laboratories Ltd Earnings Call Transcript

May 22, 2025 / 06:30 AM GMT
Release Date Price: ₹91.53 (+3.39%)

Key Points

Positve
  • Zim Laboratories Ltd (BOM:541400) reported a total operating income of INR 1,087 million for Q4 FY25, reflecting a 12.9% increase on a quarter-to-quarter basis.
  • The company's pharmaceutical segment contributed 75% of the total revenue, indicating a strong performance in its core business.
  • Export markets accounted for 83% of the total revenue, showcasing the company's successful international expansion.
  • The innovation-led segments, including new innovative products, contributed significantly to revenue, accounting for 16.5% of total revenue.
  • Zim Laboratories Ltd (BOM:541400) completed key strategic capital projects, including a dedicated neurology suite and a specialized liquid and pellet technology suite, enhancing its infrastructure and innovation capabilities.
Negative
  • Despite the growth in innovative segments, the company's overall margins have not shown significant improvement, with EBITA margin only slightly increasing from 11% to 12%.
  • The company faced a 7.7% decline in total operating income on a year-to-year basis for Q4 FY25.
  • There was a 39.7% decline in profit after tax compared to Q4 FY24, indicating challenges in maintaining profitability.
  • The domestic market revenue declined from INR 64.6 crores in FY24 to INR 53.6 crores in FY25, partly due to voluntary reduction in low-margin business and market headwinds.
  • The finance cost increased to INR 114 million, up from INR 69 million last year, primarily due to increased borrowing, impacting the company's financial health.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ZIML.NS - Zim Laboratories Ltd
Q4 2025 ZIM Laboratories Ltd Earnings Call
May 22, 2025 / 06:30AM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Zim Laboratories Limited Q4 and F 525 awnings conference call hosted by Go India advisors. As a reminder, all participant line will be in listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during the conference call, please signal an operator by pressing start and 0 on your touchdown phone. Please note that this conference is being recorded.

I now hand the conference over to Mr. Depika Sharma from Gondia advisors.

Thank you and over to you, ma'am.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot